Phentermine Dosing and Management for Weight Loss

Introduction to Phentermine Therapy

The American College of Cardiology and other guideline societies recommend starting phentermine at 15 mg once daily, with a maximum dose of 37.5 mg daily, based on response and tolerability, with discontinuation required if less than 5% weight loss is achieved after 12 weeks 1

Initial dose: Start at 15 mg daily for most patients, as recommended by the American Academy of Family Physicians 1
Maximum dose: 37.5 mg once daily, as recommended by the American College of Cardiology 1

Ultra-low starting dose: 8 mg up to 3 times daily, approximately 30 minutes before meals, may be used for patients requiring gentler titration or at higher risk for side effects, as suggested by the Endocrine Society 2, 1

Discontinue phentermine if the patient achieves less than 5% weight loss after 12 weeks on the maximum tolerated dose, as recommended by the American Heart Association 1, 2
Assess weight loss response at 12 weeks, and consider alternative therapies if less than 5% weight loss is achieved, as recommended by the Obesity Society 1

Monitor blood pressure and heart rate at every visit, as phentermine's sympathomimetic effects can elevate both parameters, as recommended by the American College of Cardiology 2, 1

Mean weight loss is approximately 5.1% at 28 weeks compared with placebo, as reported by the National Institutes of Health 1
In a 28-week trial with 15 mg daily: 46% achieved ≥5% weight loss and 20.8% achieved ≥10% weight loss, as reported by the American Journal of Clinical Nutrition 1

Younger patients without active coronary disease, uncontrolled hypertension, or cardiovascular risk factors are the most appropriate candidates for phentermine therapy, as recommended by the American Heart Association 4, 1

For patients with cardiovascular concerns or contraindications to phentermine, consider orlistat (works via gastrointestinal lipase inhibition rather than sympathetic nervous system activation), as recommended by the American Gastroenterological Association 2, 3
GLP-1 receptor agonists (semaglutide 2.4 mg or liraglutide 3.0 mg) offer superior efficacy with different safety profiles and no cardiovascular stimulation, as reported by the Endocrine Society 2